References
- Fauci, A. S. 2001. Infectious diseases: considerations for the 21st century. Clin. Infect. Dis. 32: 675-685. https://doi.org/10.1086/319235
- Leroux-Roels, G. 2010. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28 Suppl 3: C25-C36. https://doi.org/10.1016/j.vaccine.2010.07.021
- Chan, E. H., T. F. Brewer, L. C. Madoff, M. P. Pollack, A. L. Sonricker, M. Keller, C. C. Freifeld, M. Blench, A. Mawudeku, and J. S. Brownstein. 2010. Global capacity for emerging infectious disease detection. Proc. Natl. Acad. Sci. U. S. A. 107: 21701-21706. https://doi.org/10.1073/pnas.1006219107
- WHO Ebola Response Team. 2014. Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N. Engl. J. Med. 371: 1481-1495. https://doi.org/10.1056/NEJMoa1411100
- Riese, P., K. Schulze, T. Ebensen, B. Prochnow, and C. A. Guzman. 2013. Vaccine adjuvants: key tools for innovative vaccine design. Curr. Top. Med. Chem. 13: 2562-2580. https://doi.org/10.2174/15680266113136660183
- Baxter D. 2007. Active and passive immunity, vaccine types, excipients and licensing. Occup. Med. (Lond). 57: 552-556. https://doi.org/10.1093/occmed/kqm110
- Reed, S. G., M. T. Orr, and C. B. Fox. 2013. Key roles of adjuvants in modern vaccines. Nat. Med. 19: 1597-1608. https://doi.org/10.1038/nm.3409
- Glenny, A. T., C. G. Pope, H. Waddington, and U. Wallace. 1926. Immunological notes. XVII-XXIV. J. Pathol. Bacteriol. 29: 31-40. https://doi.org/10.1002/path.1700290106
- Brewer, J. M. 2006. (How) do aluminium adjuvants work?. Immunol. Lett. 102: 10-15. https://doi.org/10.1016/j.imlet.2005.08.002
- Lindblad, E. B. 2004. Aluminium adjuvants--in retrospect and prospect. Vaccine 22: 3658-3668. https://doi.org/10.1016/j.vaccine.2004.03.032
- Glenny, A. T., and C. G. Pope. 1925. The antigenic effect of intravenous injection of diphtheria toxin. J. Pathol. Bacteriol. 28: 273-278. https://doi.org/10.1002/path.1700280217
- Hutchison, S., R. A. Benson, V. B. Gibson, A. H. Pollock, P. Garside, and J. M. Brewer. 2012. Antigen depot is not required for alum adjuvanticity. FASEB J. 26: 1272-1279. https://doi.org/10.1096/fj.11-184556
- Awate, S., L. A. Babiuk, and G. Mutwiri. 2013. Mechanisms of action of adjuvants. Front. Immunol. 4: 114.
- Marrack, P., A. S. McKee, and M. W. Munks. 2009. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9: 287-293. https://doi.org/10.1038/nri2510
- Reed, S. G., S. Bertholet, R. N. Coler, and M. Friede. 2009. New horizons in adjuvants for vaccine development. Trends Immunol. 30: 23-32. https://doi.org/10.1016/j.it.2008.09.006
- Gupta, R. K. 1998. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32: 155-172. https://doi.org/10.1016/S0169-409X(98)00008-8
- O'Hagan, D. T., G. S. Ott, E. De Gregorio, and A. Seubert. 2012. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 30: 4341-4348. https://doi.org/10.1016/j.vaccine.2011.09.061
- Podda, A. 2001. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19: 2673-2680. https://doi.org/10.1016/S0264-410X(00)00499-0
- Gasparini, R., F. Schioppa, M. Lattanzi, M. Barone, D. Casula, M. Pellegrini, K. Veitch, and N. Gaitatzis. 2010. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int. J. Clin. Pract. 64: 432-438. https://doi.org/10.1111/j.1742-1241.2009.02309.x
- Calabro, S., M. Tortoli, B. C. Baudner, A. Pacitto, M. Cortese, D. T. O'Hagan, G. E. De, A. Seubert, and A. Wack. 2011. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29: 1812-1823. https://doi.org/10.1016/j.vaccine.2010.12.090
-
O'Hagan, D. T., G. S. Ott, G. V. Nest, R. Rappuoli, and G. D. Giudice. 2013. The history of MF59(
$^{(R)}$ ) adjuvant: a phoenix that arose from the ashes. Expert Rev. Vaccines 12: 13-30. https://doi.org/10.1586/erv.12.140 - Morel, S., A. Didierlaurent, P. Bourguignon, S. Delhaye, B. Baras, V. Jacob, C. Planty, A. Elouahabi, P. Harvengt, H. Carlsen, A. Kielland, P. Chomez, N. Garcon, and M. M. Van. 2011. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29: 2461-2473. https://doi.org/10.1016/j.vaccine.2011.01.011
- Brito, L. A., and D. T. O'Hagan. 2014. Designing and building the next generation of improved vaccine adjuvants. J. Control Release 190: 563-579. https://doi.org/10.1016/j.jconrel.2014.06.027
- Almeida, J. D., D. C. Edwards, C. M. Brand, and T. D. Heath. 1975. Formation of virosomes from influenza subunits and liposomes. Lancet 2: 899-901.
- Moser, C., M. Amacker, A. R. Kammer, S. Rasi, N. Westerfeld, and R. Zurbriggen. 2007. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev. Vaccines 6: 711-721. https://doi.org/10.1586/14760584.6.5.711
- Cusi, M. G. 2006. Applications of influenza virosomes as a delivery system. Hum. Vaccin. 2: 1-7. https://doi.org/10.4161/hv.2.1.2494
- Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1: 135-145. https://doi.org/10.1038/35100529
- Coffman, R. L., A. Sher, and R. A. Seder. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503. https://doi.org/10.1016/j.immuni.2010.10.002
- Gustafson, G. L., and M. J. Rhodes. 1992. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res. Immunol. 143: 483-488. https://doi.org/10.1016/0923-2494(92)80058-S
- Garcon, N., P. Chomez, and M. M. Van. 2007. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6: 723-739. https://doi.org/10.1586/14760584.6.5.723
- Descamps, D., K. Hardt, B. Spiessens, P. Izurieta, T. Verstraeten, T. Breuer, and G. Dubin. 2009. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum. Vaccin. 5: 332-340. https://doi.org/10.4161/hv.5.5.7211
- Beran, J. 2008. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin. Biol. Ther. 8: 235-247. https://doi.org/10.1517/14712598.8.2.235
- Didierlaurent, A. M., S. Morel, L. Lockman, S. L. Giannini, M. Bisteau, H. Carlsen, A. Kielland, O. Vosters, N. Vanderheyde, F. Schiavetti, D. Larocque, M. M. Van, and N. Garcon. 2009. AS04, an aluminum salt- and TLR4 agonist- based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183: 6186-6197. https://doi.org/10.4049/jimmunol.0901474
- Krieg, A. M. 2006. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5: 471-484. https://doi.org/10.1038/nrd2059
- Eng, N. F., N. Bhardwaj, R. Mulligan, and F. az-Mitoma. 2013. The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV review. Hum. Vaccin. Immunother. 9: 1661-1672. https://doi.org/10.4161/hv.24715
- Hasegawa, H., T. Ichinohe, A. Ainai, S. Tamura, and T. Kurata. 2009. Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses. Ther. Clin. Risk Manag. 5: 125-132.
- Duthie, M. S., H. P. Windish, C. B. Fox, and S. G. Reed. 2011. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239: 178-196. https://doi.org/10.1111/j.1600-065X.2010.00978.x
- Taylor, D. N., J. J. Treanor, E. A. Sheldon, C. Johnson, S. Umlauf, L. Song, U. Kavita, G. Liu, L. Tussey, K. Ozer, T. Hofstaetter, and A. Shaw. 2012. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 30: 5761-5769. https://doi.org/10.1016/j.vaccine.2012.06.086
- Turley, C. B., R. E. Rupp, C. Johnson, D. N. Taylor, J. Wolfson, L. Tussey, U. Kavita, L. Stanberry, and A. Shaw. 2011. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29: 5145-5152. https://doi.org/10.1016/j.vaccine.2011.05.041
- Morein, B., B. Sundquist, S. Hoglund, K. Dalsgaard, and A. Osterhaus. 1984. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308: 457-460. https://doi.org/10.1038/308457a0
- Garcia, A., and J. B. De Sanctis. 2014. An overview of adjuvant formulations and delivery systems. APMIS 122: 257-267. https://doi.org/10.1111/apm.12143
-
Lovgren, B. K., B. Morein, and A. D. Osterhaus. 2011. ISCOM technology-based Matrix
$M^{TM}$ adjuvant: success in future vaccines relies on formulation. Expert Rev. Vaccines 10: 401-403. https://doi.org/10.1586/erv.11.25 -
Cummings, J. F., M. D. Spring, R. J. Schwenk, C. F. Ockenhouse, K. E. Kester, M. E. Polhemus, D. S. Walsh, I. K. Yoon, C. Prosperi, L. Y. Juompan, D. E. Lanar, U. Krzych, B. T. Hall, L. A. Ware, V. A. Stewart, J. Williams, M. Dowler, R. K. Nielsen, C. J. Hillier, B. K. Giersing, F. Dubovsky, E. Malkin, K. Tucker, M. C. Dubois, J. D. Cohen, W. R. Ballou, and D. G. Heppner, Jr. 2010. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2
$CD4^+$ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine 28: 5135-5144. https://doi.org/10.1016/j.vaccine.2009.08.046 - Oleszycka, E., and E. C. Lavelle. 2014. Immunomodulatory properties of the vaccine adjuvant alum. Curr. Opin. Immunol. 28: 1-5. https://doi.org/10.1016/j.coi.2013.12.007
- De, G. E., E. Tritto, and R. Rappuoli. 2008. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol. 38: 2068-2071. https://doi.org/10.1002/eji.200838648
- O'Hagan, D. T., G. S. Ott, and N. G. Van. 1997. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol. Med. Today 3: 69-75. https://doi.org/10.1016/S1357-4310(96)10058-7
- Garcon, N., D. W. Vaughn, and A. M. Didierlaurent. 2012. Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines 11: 349-366. https://doi.org/10.1586/erv.11.192
- Atmar, R. L., and W. A. Keitel. 2009. Adjuvants for pandemic influenza vaccines. Curr. Top. Microbiol. Immunol. 333: 323-344.
- Schwendener, R. A. 2014. Liposomes as vaccine delivery systems: a review of the recent advances. Ther. Adv. Vaccines 2: 159-182. https://doi.org/10.1177/2051013614541440
- Moser, C., M. Muller, M. D. Kaeser, U. Weydemann, and M. Amacker. 2013. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev. Vaccines 12: 779-791. https://doi.org/10.1586/14760584.2013.811195
- Garcon, N., M. Wettendorff, and M. M. Van. 2011. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin. Biol. Ther. 11: 667-677. https://doi.org/10.1517/14712598.2011.573624
Cited by
- Blood Interferon Signatures Putatively Link Lack of Protection Conferred by the RTS,S Recombinant Malaria Vaccine to an Antigen-specific IgE Response vol.4, pp.None, 2015, https://doi.org/10.12688/f1000research.7093.2
- QS-21: A Potent Vaccine Adjuvant vol.3, pp.4, 2015, https://doi.org/10.4172/2329-6836.1000e113
- Communicate, educate: tackling misconceptions to boost vaccine uptake vol.10, pp.9, 2015, https://doi.org/10.2217/fvl.15.74
- In silico designing of some agonists of toll-like receptor 5 as a novel vaccine adjuvant candidates vol.5, pp.1, 2016, https://doi.org/10.1007/s13721-016-0138-1
- Prospects for the use of sulfated polysaccharides from brown seaweeds as vaccine adjuvants vol.42, pp.6, 2016, https://doi.org/10.1134/s1063074016060055
- Adjuvants: Classification, Modus Operandi , and Licensing vol.2016, pp.None, 2015, https://doi.org/10.1155/2016/1459394
- HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost vol.11, pp.1, 2015, https://doi.org/10.1371/journal.pone.0145637
- Novel platform technology for modular mucosal vaccine that protects against streptococcus vol.6, pp.None, 2015, https://doi.org/10.1038/srep39274
- Influenza infection in human host: challenges in making a better influenza vaccine vol.14, pp.4, 2015, https://doi.org/10.1586/14787210.2016.1155450
- Anti-Infectious Human Vaccination in Historical Perspective vol.35, pp.3, 2015, https://doi.org/10.3109/08830185.2015.1082177
- New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design vol.15, pp.8, 2015, https://doi.org/10.1586/14760584.2016.1158108
- Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis vol.15, pp.8, 2015, https://doi.org/10.1586/14760584.2016.1161510
- Conjugation with an Inulin–Chitosan Adjuvant Markedly Improves the Immunogenicity of Mycobacterium tuberculosis CFP10-TB10.4 Fusion Protein vol.13, pp.11, 2015, https://doi.org/10.1021/acs.molpharmaceut.6b00138
- Host‐ and pathogen‐derived adjuvant coatings on protein nanoparticle vaccines vol.2, pp.1, 2017, https://doi.org/10.1002/btm2.10052
- Vaccine adjuvants: smart components to boost the immune system vol.40, pp.11, 2015, https://doi.org/10.1007/s12272-017-0969-z
- A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles vol.13, pp.11, 2015, https://doi.org/10.1080/21645515.2017.1369639
- The Use of Xanthan Gum as Vaccine Adjuvant: An Evaluation of Immunostimulatory Potential in BALB/c Mice and Cytotoxicity In Vitro vol.2017, pp.None, 2015, https://doi.org/10.1155/2017/3925024
- Innovative Approaches to Improve Anti-Infective Vaccine Efficacy vol.57, pp.None, 2015, https://doi.org/10.1146/annurev-pharmtox-010716-104718
- Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection vol.16, pp.5, 2015, https://doi.org/10.1080/14760584.2017.1295853
- A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries vol.16, pp.6, 2017, https://doi.org/10.1080/14760584.2017.1324302
- Near-Infrared 1064 nm Laser Modulates Migratory Dendritic Cells To Augment the Immune Response to Intradermal Influenza Vaccine vol.199, pp.4, 2015, https://doi.org/10.4049/jimmunol.1601873
- Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells vol.12, pp.10, 2017, https://doi.org/10.1371/journal.pone.0185843
- Immune response effects of diverse vaccine antigen attachment ways based on the self-made nanoemulsion adjuvant in systemic MRSA infection vol.8, pp.19, 2015, https://doi.org/10.1039/c8ra00154e
- A comprehensive analysis of Italian web pages mentioning squalene-based influenza vaccine adjuvants reveals a high prevalence of misinformation vol.14, pp.4, 2015, https://doi.org/10.1080/21645515.2017.1407483
- Immunoinformatics Approach for Epitope-Based Peptide Vaccine Design and Active Site Prediction against Polyprotein of Emerging Oropouche Virus vol.2018, pp.None, 2015, https://doi.org/10.1155/2018/6718083
- The Sulfated Polysaccharides of Brown Algae and Products of Their Enzymatic Transformation as Potential Vaccine Adjuvants vol.13, pp.8, 2018, https://doi.org/10.1177/1934578x1801300837
- Alum/Toll-Like Receptor 7 Adjuvant Enhances the Expansion of Memory B Cell Compartment Within the Draining Lymph Node vol.9, pp.None, 2015, https://doi.org/10.3389/fimmu.2018.00641
- RIG-I-Like Receptors as Novel Targets for Pan-Antivirals and Vaccine Adjuvants Against Emerging and Re-Emerging Viral Infections vol.9, pp.None, 2015, https://doi.org/10.3389/fimmu.2018.01379
- DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination vol.9, pp.None, 2015, https://doi.org/10.3389/fimmu.2018.02619
- Proteomics, Bioinformatics and Structure-Function Antigen Mining For Gonorrhea Vaccines vol.9, pp.None, 2015, https://doi.org/10.3389/fimmu.2018.02793
- Prospects on the Use of Schizochytrium sp. to Develop Oral Vaccines vol.9, pp.None, 2015, https://doi.org/10.3389/fmicb.2018.02506
- Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality vol.15, pp.3, 2018, https://doi.org/10.1021/acs.molpharmaceut.7b00933
- Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants vol.61, pp.3, 2015, https://doi.org/10.1021/acs.jmedchem.7b01468
- Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice vol.207, pp.2, 2015, https://doi.org/10.1007/s00430-018-0535-4
- CYTOTOXIC PROPERTIES OF TRITERPENE SAPONIN TAUROSID SX1 AND ITS EFFECT ON HUMAN IMMUNODEFICIENCY VIRUS AND INFLUENZA VIRUS INFECTION IN MICE vol.63, pp.3, 2018, https://doi.org/10.18821/0507-4088-2018-63-3-123-129
- Harnessing T Follicular Helper Cell Responses for HIV Vaccine Development vol.10, pp.6, 2015, https://doi.org/10.3390/v10060336
- “Gnothi Seauton” : Leveraging the Host Response to Improve Influenza Virus Vaccine Efficacy vol.6, pp.2, 2015, https://doi.org/10.3390/vaccines6020023
- Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice vol.13, pp.8, 2018, https://doi.org/10.1371/journal.pone.0202961
- Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors vol.86, pp.9, 2015, https://doi.org/10.1128/iai.00114-18
- Microneedle arrays for vaccine delivery: the possibilities, challenges and use of nanoparticles as a combinatorial approach for enhanced vaccine immunogenicity vol.15, pp.9, 2015, https://doi.org/10.1080/17425247.2018.1505860
- Adjuvant Potential of Poly-α-L-Glutamine from the Cell Wall of Mycobacterium tuberculosis vol.86, pp.10, 2015, https://doi.org/10.1128/iai.00537-18
- Immunogenicity and Protective Activity of a Chimeric Protein Based on the Domain III of the Tick-Borne Encephalitis Virus E Protein and the OmpF Porin of Yersinia pseudotuberculosis Incorporated int vol.19, pp.10, 2015, https://doi.org/10.3390/ijms19102988
- Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis vol.8, pp.None, 2018, https://doi.org/10.1038/s41598-018-29858-w
- Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity vol.15, pp.1, 2015, https://doi.org/10.1186/s12985-018-1035-2
- Comparison of local reaction at injection site following intramuscular administration with three commercial atrophic rhinitis vaccines in pigs vol.41, pp.4, 2015, https://doi.org/10.7853/kjvs.2018.41.4.251
- Rational Design and In Vivo Characterization of Vaccine Adjuvants vol.59, pp.3, 2018, https://doi.org/10.1093/ilar/ily018
- Single-dose Ag85B-ESAT6–loaded poly(lactic- co -glycolic acid) nanoparticles confer protective immunity against tuberculosis vol.14, pp.None, 2015, https://doi.org/10.2147/ijn.s172391
- Adjuvants in vaccines registered for human use vol.69, pp.6, 2015, https://doi.org/10.5937/arhfarm1906406f
- Plasmodium genomics: an approach for learning about and ending human malaria vol.118, pp.1, 2015, https://doi.org/10.1007/s00436-018-6127-9
- New Insights on the Adjuvant Properties of the Leishmania infantum Eukaryotic Initiation Factor vol.2019, pp.None, 2019, https://doi.org/10.1155/2019/9124326
- ERdj5 in Innate Immune Cells Is a Crucial Factor for the Mucosal Adjuvanticity of Cholera Toxin vol.10, pp.None, 2015, https://doi.org/10.3389/fimmu.2019.01249
- The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization vol.9, pp.None, 2015, https://doi.org/10.3389/fcimb.2019.00031
- Osmolytes in vaccine production, flocculation and storage: a critical review vol.15, pp.2, 2019, https://doi.org/10.1080/21645515.2018.1526585
- Isolation of Antimicrobial Peptide from Food Protein Hydrolysates: An Overview vol.797, pp.None, 2015, https://doi.org/10.4028/www.scientific.net/kem.797.168
- Glucan Particles Are a Powerful Adjuvant for the HBsAg, Favoring Antiviral Immunity vol.16, pp.5, 2015, https://doi.org/10.1021/acs.molpharmaceut.8b01322
- Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for vol.87, pp.6, 2019, https://doi.org/10.1128/iai.00911-18
- Nanostructured cochleates: a multi-layered platform for cellular transportation of therapeutics vol.45, pp.6, 2019, https://doi.org/10.1080/03639045.2019.1583757
- Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible? vol.45, pp.6, 2015, https://doi.org/10.1080/03639045.2019.1583758
- Adjuvant activity of multimolecular complexes based on Glycyrrhiza glabra saponins, lipids, and influenza virus glycoproteins vol.164, pp.7, 2015, https://doi.org/10.1007/s00705-019-04273-2
- Protease-Activated Receptor 2 Agonist as Adjuvant: Augmenting Development of Protective Memory CD8 T Cell Responses Induced by Influenza Virosomes vol.203, pp.2, 2015, https://doi.org/10.4049/jimmunol.1800915
- Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity vol.11, pp.30, 2015, https://doi.org/10.1021/acsami.9b08295
- Lipidic Aminoglycoside Derivatives: A New Class of Immunomodulators Inducing a Potent Innate Immune Stimulation vol.6, pp.16, 2015, https://doi.org/10.1002/advs.201900288
- Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection vol.7, pp.3, 2015, https://doi.org/10.3390/vaccines7030072
- Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice vol.208, pp.6, 2015, https://doi.org/10.1007/s00430-019-00606-9
- Preparation of Squalene Oil-Based Emulsion Adjuvants Employing a Self-Emulsifying Drug Delivery System and Assessment of Mycoplasma hyopneumoniae -Specific Antibody Titers in BALB/c Mice vol.11, pp.12, 2015, https://doi.org/10.3390/pharmaceutics11120667
- Engineering a novel subunit vaccine against SARS-CoV-2 by exploring immunoinformatics approach vol.21, pp.None, 2015, https://doi.org/10.1016/j.imu.2020.100478
- Personalized Human Papillomavirus Vaccination for Persistence of Immunity for Cervical Cancer Prevention: A Critical Review With Experts' Opinions vol.10, pp.None, 2015, https://doi.org/10.3389/fonc.2020.00548
- Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies vol.12, pp.1, 2015, https://doi.org/10.3390/pharmaceutics12010030
- Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs vol.11, pp.None, 2015, https://doi.org/10.3389/fimmu.2020.01100
- Tuning Subunit Vaccines with Novel TLR Triagonist Adjuvants to Generate Protective Immune Responses against Coxiella burnetii vol.204, pp.3, 2020, https://doi.org/10.4049/jimmunol.1900991
- Potential Zika Vaccine: Encapsulated Nanocomplex Promotes Both T H 1/T H 2 Responses in Mice vol.3, pp.3, 2015, https://doi.org/10.1002/adtp.201900197
- Comparative analysis of two HIV-1 multiepitope polypeptides for stimulation of immune responses in BALB/c mice vol.119, pp.None, 2020, https://doi.org/10.1016/j.molimm.2020.01.013
- Laser adjuvant for vaccination vol.34, pp.3, 2020, https://doi.org/10.1096/fj.201902164r
- MERS-CoV Spike Protein Vaccine and Inactivated Influenza Vaccine Formulated with Single Strand RNA Adjuvant Induce T-Cell Activation through Intranasal Immunization in Mice vol.12, pp.5, 2020, https://doi.org/10.3390/pharmaceutics12050441
- C-di-GMP with influenza vaccine showed enhanced and shifted immune responses in microneedle vaccination in the skin vol.10, pp.3, 2015, https://doi.org/10.1007/s13346-020-00728-1
- The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation vol.8, pp.2, 2015, https://doi.org/10.3390/vaccines8020251
- Polysaccharide PCP-I isolated from Poria cocos enhances the immunogenicity and protection of an anthrax protective antigen-based vaccine vol.16, pp.7, 2020, https://doi.org/10.1080/21645515.2019.1675457
- Pichia pastoris: A highly successful expression system for optimal synthesis of heterologous proteins vol.235, pp.9, 2015, https://doi.org/10.1002/jcp.29583
- Evaluation of CpG-ODN-Adjuvanted Toxoplasma gondii Virus-Like Particle Vaccine upon One, Two, and Three Immunizations vol.12, pp.10, 2015, https://doi.org/10.3390/pharmaceutics12100989
- An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid-β vol.77, pp.4, 2015, https://doi.org/10.3233/jad-200413
- Biotin Functionalized Self‐Assembled Peptide Nanofiber as an Adjuvant for Immunomodulatory Response vol.15, pp.12, 2015, https://doi.org/10.1002/biot.202000100
- Development of an in silico multi-epitope vaccine against SARS-COV-2 by précised immune-informatics approaches vol.27, pp.None, 2015, https://doi.org/10.1016/j.imu.2021.100781
- Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response vol.10, pp.1, 2021, https://doi.org/10.1080/22221751.2021.1891002
- Polyphosphazenes as Adjuvants for Animal Vaccines and Other Medical Applications vol.9, pp.None, 2015, https://doi.org/10.3389/fbioe.2021.625482
- Subunit Vaccines Using TLR Triagonist Combination Adjuvants Provide Protection Against Coxiella burnetii While Minimizing Reactogenic Responses vol.12, pp.None, 2015, https://doi.org/10.3389/fimmu.2021.653092
- Enhancing Immunity with Nanomedicine: Employing Nanoparticles to Harness the Immune System vol.15, pp.1, 2021, https://doi.org/10.1021/acsnano.0c08913
- Rational design of multi epitope-based subunit vaccine by exploring MERS-COV proteome: Reverse vaccinology and molecular docking approach vol.16, pp.2, 2021, https://doi.org/10.1371/journal.pone.0245072
- Developing a Vaccine to Block West Nile Virus Transmission: In Silico Studies, Molecular Characterization, Expression, and Blocking Activity of Culex pipiens mosGCTL-1 vol.10, pp.2, 2015, https://doi.org/10.3390/pathogens10020218
- The Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model vol.13, pp.2, 2015, https://doi.org/10.3390/pharmaceutics13020205
- High‐ and low‐molecular‐weight chitosan act as adjuvants during single‐dose influenza A virus protein vaccination through distinct mechanisms vol.118, pp.3, 2015, https://doi.org/10.1002/bit.27647
- Silicone Oil-Based Nanoadjuvants as Candidates for a New Formulation of Intranasal Vaccines vol.9, pp.3, 2021, https://doi.org/10.3390/vaccines9030234
- Immuno-Informatics Analysis of Pakistan-Based HCV Subtype-3a for Chimeric Polypeptide Vaccine Design vol.9, pp.3, 2021, https://doi.org/10.3390/vaccines9030293
- Analyzing the Research Evolution in Response to COVID-19 vol.10, pp.4, 2015, https://doi.org/10.3390/ijgi10040237
- Design of Trehalose‐Based Amide/Sulfonamide C‐type Lectin Receptor Signaling Compounds vol.16, pp.8, 2015, https://doi.org/10.1002/cmdc.202000775
- Systems Biology behind Immunoprotection of Both Sheep and Goats after Sungri/96 PPRV Vaccination vol.6, pp.2, 2015, https://doi.org/10.1128/msystems.00820-20
- Advancements in protein nanoparticle vaccine platforms to combat infectious disease vol.13, pp.3, 2015, https://doi.org/10.1002/wnan.1681
- HIV-1 Accessory Proteins: Which one is Potentially Effective in Diagnosis and Vaccine Development? vol.28, pp.6, 2015, https://doi.org/10.2174/0929866528999201231213610
- Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines vol.9, pp.6, 2015, https://doi.org/10.3390/vaccines9060563
- Combination Adjuvants Affect the Magnitude of Effector-Like Memory CD8 T Cells and Protection against Listeriosis vol.89, pp.7, 2015, https://doi.org/10.1128/iai.00768-20
- Evaluation of immunogenicity and protection mediated by Lawsonia intracellularis subunit vaccines vol.237, pp.None, 2015, https://doi.org/10.1016/j.vetimm.2021.110256
- Design, expression, and purification of a multi-epitope vaccine against Helicobacter Pylori based on Melittin as an adjuvant vol.157, pp.None, 2015, https://doi.org/10.1016/j.micpath.2021.104970
- Monophosphoryl Lipid A and Poly I:C Combination Adjuvant Promoted Ovalbumin-Specific Cell Mediated Immunity in Mice Model vol.10, pp.9, 2015, https://doi.org/10.3390/biology10090908
- COVID-19 vaccine platforms: Delivering on a promise? vol.17, pp.9, 2015, https://doi.org/10.1080/21645515.2021.1911204
- Designing a Multi-Epitope Vaccine against Chlamydia trachomatis by Employing Integrated Core Proteomics, Immuno-Informatics and In Silico Approaches vol.10, pp.10, 2015, https://doi.org/10.3390/biology10100997
- Proteome-Wide Mapping and Reverse Vaccinology Approaches to Design a Multi-Epitope Vaccine against Clostridium perfringens vol.9, pp.10, 2015, https://doi.org/10.3390/vaccines9101079
- Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants vol.39, pp.48, 2015, https://doi.org/10.1016/j.vaccine.2021.10.066
- Designing novel epitope-based polyvalent vaccines against herpes simplex virus-1 and 2 exploiting the immunoinformatics approach vol.39, pp.17, 2021, https://doi.org/10.1080/07391102.2020.1803969
- PPAR agonists as effective adjuvants for COVID-19 vaccines, by modifying immunogenetics: a review of literature vol.19, pp.1, 2021, https://doi.org/10.1186/s43141-021-00179-2
- Potentiation of Recombinant NP and M1-Induced Cellular Immune Responses and Protection by Physical Radiofrequency Adjuvant vol.9, pp.12, 2021, https://doi.org/10.3390/vaccines9121382
- Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach vol.40, pp.1, 2015, https://doi.org/10.1080/07391102.2020.1792347
- Designing of a multi-epitopes-based peptide vaccine against rift valley fever virus and its validation through integrated computational approaches vol.141, pp.None, 2022, https://doi.org/10.1016/j.compbiomed.2021.105151